



Selected opportunities in Nephrology

NGAL AS A NOVEL TARGET FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE (BIO10870)



BIO 10870 – NGAL AS A NOVEL TARGET FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE

Product factsheet

In vivo PoC

Target:

- NGAL (lipocalin2,Lnc2)
- Product:
 - NGAL (Lipocalin 2, Lnc2) could be potentially targeted with an antibody or antisens

Application:

Treatment of Chronic Kidney Disease (CKD)

Technology:

Antisens (currently in development) or blocking antibody

Rational / POC:

- The severity of renal lesions after nephron reduction varied substantially among mouse strains and required activation of EGFR.
- Lipocalin 2 (Lcn2, also known as neutrophil gelatinase–associated lipocalin [NGAL]), the most highly upregulated gene in a mouse strain which develop severe renal lesions, is not simply a marker of renal lesions, but also an active player in disease progression.
- The severity of renal lesions was dramatically reduced in Lcn2–/– mice.
- Lcn2 expression increases upon EGFR activation and Lcn2 mediates its mitogenic effect during renal deterioration.
- EGFR inhibition prevented Lcn2 upregulation and lesion development in mice expressing a dominant negative EGFR isoform. Cell proliferation was dramatically reduced in Lcn2–/– mice.
- LCN2 is increased particularly in patients who rapidly progressed to end-stage renal failure.

Patent and publication:

- Viau A. et al., J Clin Invest. 2010 Nov;120(11):4065-76. doi: 10.1172/JCI42004.
- Priority date: EP10306077.8 filed on October 1st, 2010 for "METHODS FOR PREDICTING THE PROGRESSION AND TREATING A CHRONIC KIDNEY DISEASE IN A PATIENT"






2

BIO 10870 – NGAL AS A NOVEL TARGET FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE

Proof of Concept




(A and B) Lcn2 expression evaluated by (A) immunohistochemistry and (B) Western blot in kidneys from wild-type (control) and jck mice, 3 weeks after birth. (C) LCN2 staining in kidneys from controls (n = 9) and patients with ADPKD (n = 9). (D) Urinary LCN2 excretion in patients with slow progression as compared with fast progressors toward ESRF. (E) Urinary LCN2 excretion inversely correlates with eGFR in patients with ADPKD (n = 87 for ADPKD patients).



Non Confidential

BIO 10870 – NGAL AS A NOVEL TARGET FOR THE TREATMENT OF CHRONIC **KIDNEY DISEASE**


Proof of Concept



Lesion scores of kidneys from control, 75% Nx Lcn2+/+, and Lcn2–/– FVB/N mice, 2 months after nephron reduction.

4





CONTACT:

AYMERIC.EMPEREUR@INSERM-TRANSFERT.FR

Inserm Transfert - Paris Biopark 7 Rue Watt - 75013 Paris Tel: +33 1 55 03 01 00 / Fax: +33 55 03 01 60 www.inserm-transfert.fr

Confidential

